| Name | Dechra Pharmaceuticals |
|---|---|
| Epic | DPH |
| Isin | GB0009633180 |
| Index | UK100 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 3,866.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £4,403.60 | Debt ratio | n/a |
| Shares in issue | 113.89 | Debt-to-equity ratio | n/a |
| P/E ratio | 28.4 | Assets / equity ratio | n/a |
| Total dividends per share | 12.50p | Price to book value | n/a |
| Dividend yield | 1.3 | ROCE | 31.05 |
| Dividend cover | 2.71 | EPS growth | 12 |
| Earning per share | 53.72 | 52-week high / low | 2,544.00p / 3,866.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Interim | 2023-03-09 | 2023-04-13 | 12.50p |
| Final | 2022-10-27 | 2022-11-18 | 32.89p |
| Interim | 2022-03-03 | 2022-04-07 | 12.00p |
| Final | 2021-10-28 | 2021-11-19 | 29.39p |
| Interim | 2021-03-04 | 2021-04-07 | 11.11p |
| Final | 2020-11-05 | 2020-11-27 | 24.00p |
| Interim | 2020-03-05 | 2020-04-08 | 10.29p |
| Final | 2019-10-24 | 2019-11-15 | 22.10p |
| Interim | 2019-03-07 | 2019-04-08 | 9.50p |
| Company name | Dechra Pharmaceuticals |
|---|---|
| Address | 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, United Kingdom, CW9 7UA |
| Telephone | +44 (0) 160 681 4730 |
| Website | http://www.dechra.com/ |
| Director | Position |
|---|---|
| Mr Tony Griffin | Managing Director |
| Mr Ian Page | CEO |
| Mr Paul Sandland | CFO |
| Mr Geeta Gopalan | Non-Executive Director |
| Mr John Shipsey | Non-Executive Director |
| Mr Alison Platt | Non-Executive Chairman |
| Mr Lawson Macartney | Senior Independent Director |
| Mr Lisa Bright | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 30/06/22 | 30/06/21 | 30/06/20 |
| Intangible asssets and goodwill | 730.5 | 715.8 | 692.2 |
| Investments and other non-current assets | 15.8 | 17.1 | 17.4 |
| Total non-current assets | 848.9 | 821.9 | 788.7 |
| Inventory / work in progress | 175.7 | 149.5 | 120.8 |
| Trade and other receivables | 147.8 | 124.3 | 93.9 |
| Cash and equivalents | 120.9 | 118.4 | 227.4 |
| Other current assets and asset held for resale | n/a | n/a | 6.8 |
| Total of all assets | 1293.3 | 1214.1 | 1237.6 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 158.7 | 155.8 | 137.3 |
| Long term liabilities | 467.8 | 425.5 | 462.8 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 626.5 | 581.2 | 600.1 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 666.8 | 632.9 | 637.5 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 1.1 | 1.1 | 1.1 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 164 | 147.7 | 126.4 |
| Share premium account | 413.9 | 411.6 | 409.3 |
| Total equity | 666.8 | 632.9 | 637.5 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 95.5 | 84 | 52.2 |
| Pre-tax profit | 77.6 | 74 | 40.9 |